FREMONT, Calif., Sept. 9 /PRNewswire-FirstCall/ -- WaferGen
Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of
state-of-the-art genomic analysis systems, today announced that its
corporate presentation will be webcast live at Rodman and Renshaw's
12th Annual Global Healthcare Conference, Tuesday, September 14, 2010, beginning at
12:05 p.m. Eastern Time. The
presentation may be accessed at www.wafergen.com, and will be
available for 90 days.
About WaferGen and the SmartChip Real-Time PCR System
WaferGen Biosystems, Inc. is a leader in the development,
manufacture and sale of state-of-the-art systems for genomic
analysis for the life science and pharmaceutical industries.
The company currently offers the breakthrough SmartChip
Real-Time PCR System, the next-generation Real-Time PCR system for
discovery and validation of biomarkers, or gene expression
patterns, on a single platform. The SmartChip System is
designed to provide accurate, highly sensitive and high-throughput
gene expression profiling capabilities to researchers, clinicians
and pharmaceutical companies. In addition, the company offers
an innovative fee-based service for gene-expression profiling using
the SmartChip System. For additional information, please see
http://www.wafergen.com.
Forward-Looking Statements
This press release contains certain "forward-looking
statements". Such statements include statements relating to
future events and are not historical facts, including statements
which may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words.
Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the control of the company. Actual results may
differ materially from the expectations contained in the
forward-looking statements. Factors that may cause such
differences include the risks that: (i) the company may be
unsuccessful in commercially developing its products or in
achieving market acceptance of new and relatively unproven
technologies; (ii) the company will need to raise additional
capital to meet its business requirements in the future and the
company may not be able to do so on reasonable terms or at all;
(iii) the company's proprietary intellectual property rights may
not adequately protect its products and technologies; and (iv) the
company expects intense competition in its target markets,
including from companies that have much greater resources than the
company, and there can be no assurance that the company will be
able to compete effectively. More detailed information about
the company and the risk factors that may affect the realization of
forward-looking statements is set forth in the company's filings
with the Securities and Exchange Commission, including the
company's Annual Report on Form 10-K for the year ended
December 31, 2009 and the most recent
Form 10-Q. Investors and security holders are urged to read
this document free of charge on the SEC's web site at www.sec.gov.
The company does not undertake to publicly update or revise
its forward-looking statements as a result of new information,
future events or otherwise.
SOURCE WaferGen Biosystems, Inc.
Copyright t. 9 PR Newswire